Dr. Lal Path Labs Ltd. — PPTs, 31-10-2025: Investor Presentation

Dr. Lal PathLabs reported robust performance with Q2 FY26 revenue at Rs. 731 crore, up 10.8% year-on-year. Half-year (H1 FY26) revenue reached Rs. 1400 crore, an 11.0% increase. Profit After Tax (PAT) showed strong growth, rising 16.4% in Q2 to Rs. 152 crore and 19.9% in H1 to Rs. 286 crore, with H1 EPS at Rs. 33.9. This growth is primarily driven by a 10.4% increase in sample volumes and strategic network expansion, with Swasthfit contributing 27% to H1 revenue.

Strategic focus areas include calibrated expansion into metros and deeper penetration in Tier 3/4 cities, alongside significant leverage of digital infrastructure for enhanced patient experience and operational efficiency. The company is also broadening its high-end test portfolio, including Genomics, Oncology, and Autoimmunity.

Recent notable developments include the board approving a 70% dividend (Rs 7 per share) and a 1:1 bonus issue. The Genevolve division launched cfDNA Liquid Biopsy Tests and India's first screening for early-stage liver cancer, while the company became the first in South Asia to offer Amyloid Protein Typing.

Management notes sustained volume growth and a favorable business mix. They are confident in future growth through geographic expansion, portfolio innovation, and digital enablement, aiming to maximize network utilization for sustainable, profitable growth as the diagnostics market shifts from unorganized to organized players.